Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:04 AM
Ignite Modification Date: 2025-12-25 @ 12:04 AM
NCT ID: NCT04245358
Eligibility Criteria: Inclusion Criteria: * Post-menopausal women (total cessation of menses for ≥ 1 year) according to the STRAW criteria, aged ≥ 50 to ≤ 70 years; * Diagnosis of vaginal dryness by: * Subjective dryness, any objective sign of VVA, pH\>5 as reported in the AGATA study * VHI \< 15. * Body mass index (BMI) ≥ 18.5 to ≤ 36 kg/m2; * Able to communicate adequately with the Investigator and to comply with the requirements for the entire study. Capable of and freely willing to provide written informed consent prior to participating in the study. Exclusion Criteria: * Malignancy (also leukemic infiltrates) within 5 years prior to Day 0 (except for treated basal cell/squamous cell carcinoma of the skin). * Genital bleeding. * Estrogen vaginal treatment during the study period (it was permitted only if terminated at least 6 months before study). * Systemic estrogen therapy (it was permitted only if terminated at least 6 months before study). * Subjects with illness, or other medical condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the study or be likely to lead to hospitalization during the course of the study. * Clinical evidence of acute infection currently requiring treatment (syphilis, herpes simplex, human papilloma virus, gonorrhea, chlamydia, lymphogranuloma venereum, etc.); clinical evidence or history of chronic infectious disease (i.e. tuberculosis). * Psychosis, schizophrenia, mania, depressive disorders, history of suicide attempt or suicidal ideation, or any other psychiatric illness (except for intermittent anxiety). * Known allergy to tested IMDs or its excipients. * Drug or alcohol abuse in the 12 months prior to Day 0. * Participation in an interventional clinical study or administration of any investigational agents in the previous 30 days. * Presence of any clinically significant medical condition judged by the investigator to preclude the patient's inclusion in the study
Healthy Volunteers: False
Sex: FEMALE
Minimum Age: 50 Years
Maximum Age: 70 Years
Study: NCT04245358
Study Brief:
Protocol Section: NCT04245358